“…The outcome of treatment of the acute and lymphomatous subtypes is disappointing. 7,8 Combination chemotherapy, 8 novel chemotherapeutic drugs, 8 the interferons, [9][10][11] and monoclonal antibodies against the interleukin-2 receptor 12 can all induce long-term disease-free survival in a few patients, but overall survival is only 50 percent at five months. 8,13 In contrast, the chronic and smoldering types of adult T-cell leukemia-lymphoma have a longer course, regardless of treatment, and aggressive chemotherapy may be more harmful than beneficial.…”